Direct Labeling of Monoclonal Antibody TGLA with ¹⁸⁸Re and Biological Evaluation

Monoclonal antibody TGLA is a specific targeting CD20 chimeric antibody. It can kill tumor cells and inhibit tumor cells’ growth effectively, which has been applied to clinical therapy of lymphoma cell B. Monoclonal antibody TGLA was labeled with ¹⁸⁸Re, directly and got the target compound ¹⁸⁸Re-TGLA. Moreover, this work improved the reduction conditions and labeling conditions of ¹⁸⁸Re. The labeling yield reached as high as 93% at the optimum conditions. The vitro stability was good with the radiochemical purity of more than 85% after 24 hours in vitro. The biodistribution of the ¹⁸⁸Re-TGLA in lymphoma bearing nude mice showed high uptake in tumor ((6.46±2.01)ID%/g, 24 h), implied that ¹⁸⁸Re-TGLA can be used for imaging effectively. However，in order to get better imaging, antibody fragment with short half life in vivo should be used for labeling of ¹⁸⁸Re.